Abstract 137P
Background
Recent single-cell DNA sequencing (scDNA-seq) technologies have enabled the parallel investigation of thousands of individual cells. This is required for accurately reconstructing tumour evolution, during which cancer cells acquire a multitude of different genetic alterations. Although the evolutionary analysis of scDNA-seq datasets is complex due to their unique combination of errors and missing data, several methods have been developed to infer single-cell tumour phylogenies by integrating estimates of the false positive and false negative error rates. This integration relies on the assumption that errors are uniformly distributed both within and across cells. However, this assumption does not always hold; error rates depend on sequencing coverage, which is not constant within or across cells in a sequencing experiment due to, e.g., copy-number alterations and the replication status of a cell, limiting the accuracy of existing methods.
Methods
To address this challenge, we developed PHANTOM, a novel single-cell phylogenetic method that integrates raw sequencing read counts into a statistical framework to robustly correct the errors and missing data. PHANTOM includes bootstrapping to correct for high error frequency genomic positions and a fast probabilistic heuristic based on hypothesis testing to distinguish the remaining errors from truly observed genotypes.
Results
We demonstrate the improved accuracy and robustness of our method compared to existing approaches across several simulation settings. To demonstrate its impact, we applied our method to scDNA-seq datasets comprising >25,000 cells from 31 patients with triple-negative breast cancer or high-grade serous ovarian cancer, as well as targeted scDNA-seq from a cohort of 123 patients with acute myeloid leukaemia, revealing more accurate phylogenies consistent with copy-number alterations.
Conclusions
We developed PHANTOM, a novel single-cell phylogenetic method that accurately and robustly infers single-cell tumour phylogenies. We applied PHANTOM to scDNA-seq cancer datasets, revealing its potential to investigate tumour evolution at unprecedented resolution.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Cancer Research UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - Whole exome sequencing reveals high frequency of Notch pathway mutations in Indian breast cancer cases
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract